What You Should Know:
– Foundation Medicine acquires Lexent Bio, a precision oncology company developing novel liquid biopsy platforms.
– The acquisition will accelerate Foundation Medicine’s liquid biopsy R&D and advance cancer care through an expansion of multiomics capabilities.
Foundation Medicine, Inc., announced that it has completed the acquisition of Lexent Bio, Inc., a precision oncology company located in California, developing novel multiomics liquid biopsy platforms to advance cancer care. Foundation Medicine is a molecular insights company that offers a portfolio of comprehensive genomic profiling services to connect patients to cancer treatments and advanced precision medicine. This acquisition will accelerate Foundation Medicine’s research and development strategy and expand its existing liquid biopsy platforms to advance cancer care for patients.
Acquisition Expands Foundation Medicine’s Liquid Biopsy R&D Efforts
Specifically, the acquisition enables Foundation Medicine to:
– Expand its core R&D capabilities to include a new emphasis on multiomics, including the incorporation of DNA methylation into biomarkers for cancer progression across all stages of disease, including early stage
– Expand its portfolio offerings to evaluate cancer progression in broader patient populations
– Enhance its ability to capture longitudinal data with serial patient sampling; and
– Accelerate its early R&D pipeline and support new approaches for developing targeted therapies, from discovery research through clinical development.
Lexent Bio’s novel monitoring platform is currently in development and is based on low-pass whole-genome sequencing (WGS) and DNA methylation analysis. Foundation Medicine plans to further incorporate WGS and methylation into new assay platforms to support treatment decision-making across all stages of the disease. Methylation analysis has been shown to reveal important aspects of underlying cancer biology and allows oncologists to identify patients at high risk of disease progression, potentially intervene sooner and improve patient outcomes in earlier stages of disease.
These collective capabilities will enable the expansion of Foundation Medicine’s current tumor-informed personalized cancer monitoring initiatives into universal tumor-agnostic approaches in the future.
This technology adds to Foundation Medicine’s portfolio of tissue and liquid biopsy platforms and will aim to support new approaches for developing targeted therapies, from discovery research through clinical development. With this acquisition and the integration of Lexent Bio’s monitoring platform, Foundation Medicine will expand its capabilities to support adaptive clinical trial designs and accelerate therapeutic development in both early and late-stage disease, ultimately bringing new options to oncologists and patients.
“Lexent Bio’s platforms align well with our liquid biopsy research and development strategy, which ultimately aims to bring the latest research innovations into routine clinical use in metastatic disease and at potentially earlier stages of patient care,” said Cindy Perettie, chief executive officer at Foundation Medicine. “They bring with them an accomplished group of clinicians, scientists and engineers who share our patient-centric, science-first mission to transform cancer care. We’re thrilled to welcome them to our team and look forward to their contributions to our research and development efforts to deliver new breakthroughs that advance precision medicine and patient care.”
